Adenosine A1 Receptor Antagonism Abolished the Anti-seizure Effects of Exogenous Ketone Supplementation in Wistar Albino Glaxo Rijswijk Rats

Zsolt Kovács1, Dominic P. D’Agostino2, Arpád Dobolyi3,4 and Csilla Ari2,5

1 Savaria Department of Biology, Eötvös Loránd University, Budapest, Hungary, 2 Hyperbaric Biomedical Research Laboratory, Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States, 3 Laboratory of Neuromorphology and Human Brain Tissue Bank, Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary, 4 Laboratory of Molecular and Systems Neurobiology, Department of Physiology and Neurobiology, Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary, 5 Department of Psychology, University of South Florida, Tampa, FL, United States

The state of therapeutic ketosis can be achieved by using the ketogenic diet (KD) or exogenous ketone supplementation. It was suggested previously that the adenosinergic system may be involved in the mediating effect of KD on suppressing seizure activity in different types of epilepsies, likely by means of adenosine A1 receptors (A1Rs). Thus, we tested in the present study whether exogenous ketone supplements (ketone ester: KE, 2.5 g/kg/day; ketone salt/KS + medium chain triglyceride/MCT: KSMCT, 2.5 g/kg/day) applied sub-chronically (for 7 days) by intragastric gavage can modulate absence epileptic activity in genetically absence epileptic Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats. The number of spike-wave discharges (SWDs) significantly and similarly decreased after both KE and KSMCT treatment between 3rd and 7th days of gavage. Moreover, blood beta-hydroxybutyrate (βHB) levels were significantly increased alike after KE and KSMCT gavage, compared to control levels. The SWD number and βHB levels returned to the baseline levels on the first day without ketone supplementation. To determine whether A1Rs can modify ketone supplement-evoked changes in absence epileptic activity, we applied a non-pro-epileptic dose of a specific A1R antagonist DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (intraperitoneal/i.p. 0.2 mg/kg) in combination with KSMCT (2.5 g/kg/day, gavage). As expected, DPCPX abolished the KSMCT-evoked decrease in SWD number. Thus, we concluded that application of exogenous ketone supplements may decrease absence epileptic activity in WAG/Rij rats. Moreover, our results suggest that among others the adenosinergic system, likely via A1Rs, may modulate the exogenous ketone supplements-evoked anti-seizure effects.

Keywords: ketone supplements, epilepsy, adenosine, WAG/Rij rats, ketosis, seizure

Abbreviations: A1R, adenosine A1 receptor; A2AR, adenosine A2A receptor; AcAc, acetoacetate; ATP, adenosine triphosphate; βHB, beta-hydroxybutyrate; DMSO, dimethyl sulfoxide; DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; EEG, electroencephalogram; FFT, fast Fourier transform; GABA, gamma-aminobutyric acid; i.p., intraperitoneal; KATP channels, ATP-sensitive potassium channels; KD, ketogenic diet; KS, ketone salt; KSMCT, ketone salt/KS + medium chain triglyceride/MCT; MCT, medium chain triglyceride; PT day, post-treatment control experiment/day; REM sleep, rapid eye movement sleep; S.E.M., standard error of the mean; SWD, spike-wave discharge; SWS, slow wave sleep; WAG/Rij, Wistar Albino Glaxo/Rijswijk.
INTRODUCTION

Ketogenic diet (high-fat, adequate protein, and low carbohydrate diet) and ketone supplementation (exogenous ketone supplement and/or MCT) may evoke nutritional ketosis (Kwiterovich et al., 2003; Poff et al., 2015; Kesl et al., 2016), which enhances conversion of ketone bodies such as beta-hydroxybutyrate and acetoacetate (AcAc) into acetyl-CoA to support ATP production (Yudkoff et al., 2007). Under this condition, the cells utilize ketone bodies as an alternative fuel to enhance brain energy metabolism. The classical KD and variants have proven beneficial in treating epilepsy and other disorders by decreasing seizure activity (Lefevre and Aronson, 2000; Kossoff et al., 2011), likely by modulation of GABAergic, glutamatergic, and adenosinergic processes (Yudkoff et al., 2007; Masino et al., 2011; Rhó, 2017). The exact mechanism(s) of the KD/ nutritional ketosis on epilepsy are largely unknown and remain an area of intense investigation and interest within the pharmaceutical industry.

Genetically absent epileptic WAG/Rij rats spontaneously generate absence-like seizures, and manifest spike-wave asymmetric discharges (SWDs) on the EEG. A typical SWD contains a train of asymmetric spikes and slow waves starting and ending with sharp spikes (frequency: 7–11 Hz and duration 1–30 s in WAG/Rij rats) (Coenen and Van Luijten, 2003). It was demonstrated that the hyperexcitable neurons of cortical focus in the somatosensory cortex initiate SWDs (cortical focus theory) (Meeren et al., 2002).

It has been demonstrated that, oral administration of βHB and AcAc in their free acid form is difficult to produce sustained ketosis, in contrast to ketone ester and ketone salt supplementation (D’Agostino et al., 2013; Kesl et al., 2016). It is well-known that adenosinergic system may be involved not only in the alleviating effect of KD/ketosis on epileptic seizures (mainly by means of A1Rs), but also in the modulation of absence epilepsy mechanisms (D’Alimonte et al., 2009; Masino et al., 2011; Kovács et al., 2014; Kim et al., 2016). Thus, we addressed in the present study whether (i) sub-chronically (for 7 days) applied exogenous ketone supplements (KE; KS + MCT: KSMCT) by intragastric gavage can modulate absence epileptic activity and (ii) inhibition of A1Rs by its specific antagonist can evoke changes in seizure frequency in WAG/Rij rats. At first, to investigate the influence of the ketone supplements on absence epileptic activity, we administered KE (2.5 g/kg/day) and KSMCT (2.5 g/kg/day) alone by gavage. We measured not only glucose, but also βHB levels in the blood collected from tail veins to establish the ketonemia-inducing effect of ketone supplementation as ketonemia is the clinical hallmark associated with metabolic management of seizures (Freeman et al., 1994). As we have no data on the putative effects of intraperitoneally (i.p.) injected specific A1R antagonist DPCPX on absence epileptic activity in WAG/Rij rats, we also investigated the effect of two doses (i.p. 0.2 and 0.5 mg/kg alone) on SWD number. Subsequently, to decide whether A1Rs can modify ketone supplements-evoked changes in SWD number, we applied a lower dose (i.p. 0.2 mg/kg) of DPCPX in combination with KSMCT (2.5 g/kg/day, gavage).

We hypothesized that (i) exogenous ketone supplementation evokes ketosis, and decreases absence epileptic seizures, and (ii) A1R blockade modifies the influence of exogenous ketone supplementation on SWD number. Indeed, we demonstrated that exogenous ketone supplements increased blood βHB levels and decreased SWD number when given sub-chronically and inhibition of A1Rs abolished the exogenous ketone supplements-evoked changes in SWD number in WAG/Rij rats.

MATERIALS AND METHODS

Animals

All animal treatments and surgery procedures were carried out according to the local ethical rules, which are in conformity with the guidelines of the Hungarian Act of Animal Care and Experimentation (1998, XXVIII, section 243), European Communities Council Directive 24 November 1986 (86/609/EEC) and EU Directive 2010/63/EU on the use and treatment of animals in experimental laboratories. The experimental design was approved by the Animal Care and Experimentation Committee of the Eötvös Loránd University (Savaria Campus) and National Scientific Ethical Committee on Animal Experimentation (Hungary) under license number VA/EBNTF02/85-8/2016, and was compliant with the Ethics Codex of institution. All efforts were made to minimize pain and suffering and to reduce the number of animals used.

Wistar Albino Glaxo/Rijswijk male rats (n = 33; 10 months old, 315–350 g; breeding colony of WAG/Rij rats at Eötvoš Loránd University, Savaria Campus, Szombathely, Hungary) were housed in groups 3–4 and they were single housed after surgery. Standard laboratory conditions were as follows: 12:12 h light-dark cycle (light was on from 08.00 AM to 08.00 PM); free access to water and food; air-conditioned room (at 22 ± 2°C).

Electrode Implantation and EEG Recording

Electrode implantation was carried out under Isoflurane-air mixture (2.0–2.5%) anesthesia with stainless steel screw electrodes for EEG recording (Kovács et al., 2006). Briefly, screw electrodes were placed into the bone above primary motor cortex and somatosensory cortex (A 0.8, L 1.8 and A 0.2, L 6.2, respectively) (Paxinos and Watson, 1999). A stainless steel plate (3 mm × 4 mm with one side insulated) and a screw electrode were implanted under the skin and over the masseter muscle as well as above the cerebellar cortex as reference electrode and ground electrode, respectively. The plate and electrodes were soldered to a 10-pin socket. Dentacrylate cement (Ivoclar, Liechtenstein) was used to fix electrodes and attach the socket to the skull. Lidocaine ointment (5%; EGIS, Hungary) was applied as post-operative pain relief. Rats were allowed to recover for 2 weeks. For the adaptation of rats to the experimental procedures animals were handled daily and were connected to an electroencephalograph for 5 days (adaptation to EEG recording) (Figure 1).

Electroencephalograms were recorded by an electroencephalograph (NIHON-KOHDEN, Japan) attached to a CED
FIGURE 1 | Design of experiments on five animal groups. *, days of blood glucose and βHB level measuring; DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KE, ketone ester (1,3-butanediol – acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT; PT day, post-treatment control experiment/day.

1401 mkII (Cambridge Electronic Design, Ltd, United Kingdom) data capture and analysis device (the bandwidth of the EEG recording: 0.3–150 Hz; the sampling rate 500 Hz) (Kovács et al., 2015). We recorded EEG between 2.30 PM and 5.00 PM. As handling may evoke stress-induced changes in behavior for about 30 min, which can modify SWD number (Coenen and Van Luijtenaar, 2003; Kovács et al., 2015), evaluation of SWD number, average time and total time of SWDs and sleep-waking stages were carried out between 30 and 150 min. These periods were split into 60 min sections and were evaluated separately (Kovács et al., 2006). However, normal grooming and behavior and typical SWDs (Figure 2) were observed in all animals 30 min after the connection of rats to the electroencephalograph (e.g., after KE or KSMCT gavage). SWDs
FIGURE 2 | Typical SWDs were observed in all animals 30 min after the connection of rats to the electroencephalograph in the control period (A, group 1) as well as after gavage of KE (B, 1,3-butanediol – acetoacetate diester, 2.5 g/kg/day, group 1) and KSMCT (C, ketone salt + medium chain triglyceride, 2.5 g/kg/day, group 2).

were separated from the EEG manually and checked by FFT analysis.

**Measuring of Blood Glucose and βHB Levels**

Blood glucose (mg/dl) and βHB (mmol/l) levels were measured from blood taken from the tail vein with a commercially available glucose and ketone monitoring system (Precision Xtra™, Abbott Laboratories, Abbott Park, IL, United States) (Ari et al., 2016). This ketone monitoring system only measures blood levels of βHB, thus, total blood ketone levels (βHB + AcAc + acetone) would be higher than we measured.

**Experimental Design**

Both KE (1,3-butanediol – acetoacetate diester) and KS (Na⁺/K⁺ – βHB mineral salt) were developed by D’Agostino et al. (2013; University of South Florida/USF, United States) in collaboration with Savind, Inc. (Urbana, IL, United States). Ketone salt was mixed into a 50% solution (375 mg/g pure βHB and 125 mg/g of Na⁺/K⁺ in a 1:1 ratio). MCT oil
(pharmaceutical grade; approximately 60% caprylic triglyceride and 40% capric triglyceride) was purchased from Now Foods (Bloomingdale, IL, United States). KS and MCT were also mixed in a 1:1 ratio (KSMCT) at the USF (United States). At first, we tested the tolerability and effectiveness of exogenous ketone supplementation (ad libitum access to normal rat chow + KE and KSMCT given by intragastric gavage once/day) for 7 days in the first phase of the study to assess ketonemia. Therefore, in the second phase of the study, KE (2.5 g/kg/day) and KSMCT (2.5 g/kg/day) were applied as ketone supplements alone by gavage followed by EEG recording.

Rats were assigned into five groups (Figure 1). To adapt the animals to gavage method (animal group 1/group 1, group 2 and group 5) we applied water intragastric gavage for 5 days before control treatments (between 1st and 5th day of the experiment). Then, to establish averaged control SWD numbers, SWD durations and sleep-waking stages, rats were (i) ‘treated’ by gavage of water (2.5 g/kg/day) (group 1, n = 7 and group 2, n = 7), (ii) injected i.p. by 0.5 ml saline/100 g body weight (b. w.; group 3, n = 6 and group 4, n = 6) or (iii) i.p. injected by 0.5 ml saline/100 g b. w., which injection was followed by the water gavage (2.5 g/kg/day) (30 min later; group 5, n = 7) on 5 consecutive days (5-day control period, pre-treatment control days; between 6th and 10th day of the experiment) (Figure 1). After control periods, animals of group 1 and group 2 were treated with KE (2.5 g/kg/day, group 1) and KSMCT (2.5 g/kg/day, group 2) alone for 7 consecutive days (between 11th and 17th day of the experiment) (Figure 1). Finally, the 7 days treatments by both KE and KSMCT were followed by a day of water gavage (2.5 g/kg/day; post-treatment control experiment/day; PT day) to investigate putative sustained effect of ketone supplementation on SWD number. In relation to group 3 and group 4, to investigate the effect of the specific A1R antagonist DPCPX on SWD number, 0.2 mg/kg (group 3) and 0.5 mg/kg (group 4) of DPCPX in 0.5 ml 10% DMSO/100 g b. w. were i.p. injected alone on the 11th day of the experiment (Figure 1). A previous study showed that 1–30% (v/v) DMSO solution have no effects on the values measured on the last (5th) control days (in case of b. w. and blood level of glucose and βHB) (Kovács et al., 2015). To reveal the putative influence of A1R blockade on ketone supplements-evoked changes in SWD number, combined application of (i) i.p. saline injection (0.5 ml/100 g b. w.) with KSMCT gavage (2.5 g/kg/day, between 11th and 15th day of the experiment), (ii) i.p. 0.2 mg/kg DPCPX with KSMCT (2.5 g/kg/day) on the 6th day of KSMCT gavage (16th day of the experiment; DPCPX injection preceded the gavage by 30 min) and (iii) i.p. saline injection with KSMCT gavage (last day of the experiment; group 5) were carried out (Figure 1).

To investigate the effect of ketone supplements (KE and KSMCT) on blood glucose and βHB levels we measured them on the last (5th) control day (control), on the days of the 1st and the 7th ketone supplement gavage and on PT day (on the 10th, 11th, 17th, and 18th day of experiments, respectively; group 1 and group 2) (Figure 1). The body weight of rats were also measured before treatments by ketone supplement started (5th control day: control) and after the last (7th) ketone supplement treatments (on the 10th and 17th day of experiments, respectively; group 1 and group 2).

As changes in sleep-waking ratios may modulate SWD number in WAG/Rij rats (Coenen et al., 1991; Coenen and Van Luijtelera, 2003) and as we had no prior data on putative effects of ketone supplements, DPCPX and combined application of DPCPX with KSMCT on sleep-waking stages, we investigated their effect (after 6th gavage of 2.5 g/kg KSMCT alone/group 2, i.p. 0.2 mg/kg DPCPX alone/group 3 and combined application of i.p. 0.2 mg/kg DPCPX with 2.5 g/kg KSMCT/group 5) not only on SWD number, SWD time (average time of SWDs) and discharge frequency within SWDs, but also on sleep-waking stages between 30 and 90 min. The effect of 2.5 g/kg KE (group 1) on SWD time and discharge frequency within SWDs was also investigated between 30 and 90 min. Evaluation of sleep-waking stages was performed offline by visual evaluation of the raw EEG. We distinguished wakefulness (predominantly beta/20–40 Hz and theta/6–8 Hz activity: wake; passive/active wake: without/with high slow waves of motor artifacts), SWS (sleep spindles/10–16 Hz, theta waves and some slow waves/2–4 Hz: light SWS; disappearance of sleep spindles and increasing ratio of high slow delta waves/0.5–4 Hz: deep SWS) and REM sleep (continuous theta activity without any motor artifacts) in 60 min epochs (Kovács et al., 2006).

All results (SWD number, SWD time, discharge frequency within SWDs, sleep-waking stages, b. w. as well as blood level of glucose and βHB) were expressed as means ± standard error of the mean. The pre-treatment control values were the grand average calculated (i) from the results of 5 control days (5-day control period; in relation to SWD number, SWD time, discharge frequency within SWDs and sleep-waking stages) or (ii) from the values measured on the last (5th) control days (in case of b. w. and blood level of glucose and βHB). Results were evaluated by One- or Two-way Repeated Measure Analysis of Variance and significance levels were determined by Dunnett’s Multiple Comparison Test and Bonferroni’s Post hoc Tests as were described previously (Kovács et al., 2015).

RESULTS

Effect of Exogenous Ketone Supplements on SWD Number, Blood βHB, Glucose Levels, and Body Weight

Significant decrease in SWD number was demonstrated after both KE (2.5 g/kg/day, group 1) and KSMCT (2.5 g/kg/day, group 2) treatment between 3rd and 7th days of gavage from 30 to 150 min (Figures 3A,B and Table 1) compared to control levels. Moreover, SWD numbers were similar to the control levels on PT days (2.5 g/kg water gavage) (Figures 3A,B and Table 1).

Blood βHB and glucose levels were significantly increased and unchanged, respectively, after the 1st and 7th KE (2.5 g/kg/day, group 1) or KSMCT (2.5 g/kg/day, group 2) gavage (Figures 3C–F and Table 2) compared to control levels. The βHB and glucose levels returned to the baseline (control) levels on the PT day (Figures 3C–F and Table 2).
FIGURE 3 | Effect of KE (gavage, 2.5 g/kg/day; group 1) and KSMCT (gavage, 2.5 g/kg/day; group 2) on SWD number (A,B, respectively) as well as on βHB and glucose levels (KE: C,E; KSMCT: D,F). 1KE, 1st KE application (gavage); 2KE, 2nd KE application and so on; 1KS, 1st KSMCT application (gavage); 2KS, 2nd KSMCT application and so on (KSMCT, ketone salt/KS + medium chain triglyceride/MCT); 1PT, post-treatment control experiment (2.5 g/kg water gavage); βHB, beta-hydroxybutyrate; CON, control; KE, ketone ester (1,3-butanediol – acetoacetate diester); SWD, spike-wave discharge. *p < 0.05, **p < 0.01, and ***p < 0.001 level of significance.
TABLE 1 | Effects of KE (gavage, 2.5 g/kg/day, group 1) and KSMCT (gavage, 2.5 g/kg/day, group 2) on SWD number.

| Treatments | The effect of treatment (one-way RM ANOVA; significance/F-value) | SWD number (mean ± SEM) and Dunnett’s Multiple Comparison Test (significance/q-value) |
|------------|---------------------------------------------------------------|----------------------------------------------------------------------------------|
| 30–90      | 90–150                                                        |                                                                                   |
| Control (CON) | 30–90 min: ***/*                                            | 15.5 ± 0.9                                                                        | 17.1 ± 1.6                                                                        |
| 1st KE treatment (1KE) | 8.541                                                  | 12.9 ± 2.1                                                | 12.7 ± 1.5                                                                        |
| 2nd KE treatment (2KE) | 90–150 min: ***/ 6.010                                         | 14.1 ± 1.7                                                | 13.1 ± 2.9                                                                        |
| 3rd KE treatment (3KE) | 10.0 ± 1.5                                                  | −0.827                                            | 11.1 ± 1.2                                                                        |
| 4th KE treatment (4KE) | 8.4 ± 0.9                                                   | −/3.324                                                | 8.1 ± 0.6                                                                         |
| 5th KE treatment (5KE) | 6.9 ± 0.4                                                   | −/4.271                                                | 6.9 ± 0.9                                                                         |
| 6th KE treatment (6KE) | 7.1 ± 0.5                                                   | −/5.218                                                | 7.3 ± 0.8                                                                         |
| 7th KE treatment (7KE) | 6.9 ± 0.8                                                   | −/5.046                                                | 6.4 ± 1.2                                                                         |
| Post-treatment control experiment (1PT) | 13.3 ± 1.8                                                  | −/1.343                                                | 14.1 ± 1.2                                                                         |

| Control (CON) | 30–90 min: ***/*                                            | 17.8 ± 1.2                                                                        | 17.1 ± 0.7                                                                        |
| 1st KSMCT treatment (1KS) | 14.000                                                   | 16.4 ± 1.8                                                | 15.1 ± 2.9                                                                        |
| 2nd KSMCT treatment (2KS) | 90–150 min: ***/ 5.404                                         | 13.9 ± 1.1                                                | 13.0 ± 2.3                                                                        |
| 3rd KSMCT treatment (3KS) | 11.1 ± 0.9                                                  | −/2.757                                                | 8.9 ± 1.5                                                                         |
| 4th KSMCT treatment (4KS) | 10.0 ± 0.5                                                   | −/3.361                                                | 9.6 ± 0.5                                                                         |
| 5th KSMCT treatment (5KS) | 8.0 ± 0.6                                                   | −/5.113                                                | 7.4 ± 0.9                                                                         |
| 6th KSMCT treatment (6KS) | 7.9 ± 0.5                                                   | −/6.429                                                | 7.7 ± 0.5                                                                         |
| 7th KSMCT treatment (7KS) | 7.3 ± 0.4                                                   | −/6.523                                                | 6.9 ± 0.5                                                                         |
| Post-treatment control experiment (1PT) | 15.0 ± 2.4                                                  | −/1.823                                                | 14.0 ± 2.6                                                                         |

KE, ketone ester (1,3-butanediol – acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT; SWD, spike-wave discharge. *p < 0.05, **p < 0.01, and ***p < 0.001 level of significance.

We did not find significant changes in b. w. of animals after KE (group 1) and KSMCT (group 2) application compared to control levels [b. w. of rats (g) on the 5th control day/after the 7th KE or KSMCT treatments ± SEM; control/KE: 323.3 ± 7.9/324.2 ± 8.1, q = 1.005; control/KSMCT: 335.6 ± 7.4/334.7 ± 6.7, q = 0.633].

Effect of DCPX Alone and in Combination with KSMCT on SWD Number

We demonstrated that a lower dose of DPCPX (i.p. 0.2 mg/kg, group 3) alone did not change the SWD number whereas the higher dose (i.p. 0.5 mg/kg, group 4) alone significantly increased the SWD number between 30 and 90 min after injection (Figures 4A,B and Table 3). However, the tendency in SWD number after the i.p. injection of higher DPCPX dose (control/DPCPX ± SEM: 13.5 ± 1.3/16.2 ± 1.9, t = 2.406) between 90 and 150 min was not significant (Figure 4B and Table 3).

A similar decrease in SWD number was observed after both KE and KSMCT gavage between 1st and 7th gavage days, but the change in SWD number was slightly smoother in relation to KSMCT (Figures 3A,B). Moreover, based on previous studies (Yudkoff et al., 2007; Masino et al., 2011; Rho, 2017), we hypothesized that the mechanism(s) of action on epileptic activity may be similar for KE and KSMCT. Thus, we used only
KSMCT (2.5 g/kg/day) for combined application with DPCPX (group 5). In addition, we selected the lower dose of DPCPX (0.2 mg/kg) for combined application to decrease its putative side effects and because we wanted to inhibit (antagonize) A_{1}Rs without increasing seizure activity (Figures 4A,B). As we did not find an effect of a lower DPCPX dose on behavior and as we demonstrated only a very slight and insignificant increase or decrease in SWD number, average SWD duration and discharge frequency within SWDs after its i.p. application alone (Figure 4A), we used this non-pro-epileptic dose of DPCPX (i.p. 0.2 mg/kg) in combination with KSMCT (2.5 g/kg/day) on the 6th day of KSMCT gavage, when, without DPCPX, KSMCT alone significantly decreased the SWD number (Figure 3B). As Figure 4C shows, i.p. 0.2 mg/kg DPCPX abolished the KSMCT-evoked decrease in SWD number on the 6th day of KSMCT gavage (Figures 3B, 4C and Table 4; group 5).

**Effect of KE, KSMCT, DPCPX and Combined Application of DPCPX with KSMCT on Average SWD Duration, Discharge Frequency within SWDs and on Sleep Waking Stages**

We did not find changes in the average SWD duration and discharge frequency within SWDs after application of KE (2.5 g/kg/day, 6th gavage, group 1), KSMCT (2.5 g/kg/day, 6th gavage, group 2), DPCPX (i.p. 0.2 mg/kg, group 3) alone and combined application of DPCPX (i.p. 0.2 mg/kg) with KSMCT (2.5 g/kg/day, 6th gavage, group 5) between 30 and 90 min (Table 5). Consequently, changes in the total time of SWDs paralleled the change in SWD number as shown in Table 6 (last row) (Figures 3B, 4A,C).

The total time of sleep-waking stages was not changed after application of KSMCT (6th gavage, group 2), DPCPX (i.p. 0.2 mg/kg, group 3) alone and combined application of DPCPX with KSMCT (6th gavage, group 5) between 30 and 90 min (Table 6).

**DISCUSSION**

The current study is the first to demonstrate that the sub-chronic application of exogenous ketone supplements (both KE and KSMCT) by intragastric gavage decreased absence epileptic activity, and was abolished by pharmacologic inhibition of A_{1}Rs in WAG/Rij rats.

It has been demonstrated that different types of ketogenic diets represent alternative treatment methods (metabolic-based therapies) for a broad range of seizure disorders, in which decreased epileptic activity may be related to elevations in serum ketone bodies, reduced glucose levels, suppression of insulin signaling as well as different neurotransmitter systems, such as GABAergic and adenosinergic system in different types of epilepsies (Ross et al., 1985; Van Delft et al., 2010; Sharma et al., 2015; Rho, 2017). Although the relationship between KD-evoked ketosis and seizure arrest is still unclear, it is widely accepted that high level ketosis has an important role in antiseizure/anticonvulsant effects of KD: βHB may alter metabolic pathways to increase both GABA and adenosine, which products have anticonvulsant and seizure suppressive effects (Gilbert et al., 2000; Bough et al., 2002; Neal et al., 2009; Van Delft et al., 2015).

**Table 2: Influence of KE (gavage, 2.5 g/kg/day, group 1) and KSMCT (gavage, 2.5 g/kg/day, group 2) on blood βHB and glucose levels.**

| Treatments                        | The effect of treatment (one-way RM ANOVA; significance/F-value) | Blood βHB and glucose levels (mean ± SEM) and Dunnett's Multiple Comparison Test (significance/q-value) |
|-----------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                   |                                                                  | βHB (mmol/l)                                                                                           |
| 2.5 g/kg/day KE (Figures 3C,E, group 1) |                                                                  | 0.8 ± 0.1                                                                                               |
| Control (CON)                     |                                                                  | 98.0 ± 3.8                                                                                              |
| 1st KE treatment (1KE)            | βHB: ***/50.090                                                  | 1.8 ± 0.1                                                                                               |
| 7th KE treatment (7KE)            |                                                                  | 86.4 ± 3.7                                                                                              |
| 7th KE treatment (7KE)            |                                                                  | ***/9.120                                                                                               |
| Post-treatment control experiment (1PT) |                                                                  | 1.6 ± 0.1                                                                                               |
|                                   |                                                                  | ***/7.707                                                                                               |
|                                  |                                                                  | 0.7 ± 0.1                                                                                               |
|                                   |                                                                  | −0.385                                                                                                  |
| 2.5 g/kg/day KSMCT (Figures 3D,F, group 2) |                                                                  | βHB (mmol/l)                                                                                           |
| Control (CON)                     |                                                                  | 0.9 ± 0.0                                                                                               |
| 1st KSMCT treatment (1KS)         | βHB: ***/41.180                                                  | 1.8 ± 0.2                                                                                               |
| 7th KSMCT treatment (7KS)         |                                                                  | 87.8 ± 3.6                                                                                              |
| 7th KSMCT treatment (7KS)         |                                                                  | ***/7.334                                                                                               |
| Post-treatment control experiment (1PT) |                                                                  | 1.9 ± 0.1                                                                                               |
|                                   |                                                                  | 93.3 ± 2.7                                                                                              |
|                                   |                                                                  | ***/8.011                                                                                               |
|                                  |                                                                  | −0.299                                                                                                  |
|                                   |                                                                  | −0.339                                                                                                  |
|                                   |                                                                  | 96.3 ± 5.2                                                                                              |
|                                   |                                                                  | −0.399                                                                                                  |

βHB, beta-hydroxybutyrate; KE, ketone ester (1,3-butanediol – acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT. ***p < 0.001 level of significance.
et al., 2010; Sharma et al., 2015). Nevertheless, many patients have difficulty with compliance to the KD because of gastrointestinal symptoms including vomiting, diarrhea and abdominal pain (Ross et al., 1985; Veggioetti and De Giorgis, 2014). Therefore, testing new, non-pharmacological therapeutic strategies, such as application of exogenous ketone supplements instead of strict KD (Lee et al., 2016), which supplements may sustain therapeutic levels of ketosis are needed for some individuals. Exogenous ketone supplementation may generate corresponding beneficial therapeutic effect on epileptic seizures similar to the KD because (i) exogenous ketone supplementation-evoked influences may be similar to effects of KD (such as increased adenosine level), whose actions may mediate the effects of ketone supplementation on different types of epilepsies, (ii) among others, ketone bodies (e.g., βHB) may be responsible for the mediating effects of KD/ketosis as well as ketone supplementation on epileptic seizures due to altering Krebs cycle intermediates and GABAergic activity, and (iii) ketone supplementation (both KE and KSMCT) increase blood βHB levels and evoke nutritional ketosis at levels known to preserve brain homeostasis (Figures 3C,D) (Kwiterovich et al., 2003; Yudkoff et al., 2007; Masino et al., 2011; Poff et al., 2015; Ari et al., 2016; Kesl et al., 2016; Rho, 2017). Moreover, tolerability of oral/intragastric exogenous ketone supplementation in inducing nutritional ketosis is consistent with previous studies (Kesl et al., 2016), and provides a rationale for circumventing the dietary restriction of the KD or to enhance ketogenesis in less restrictive modified versions.

It was previously demonstrated that KD/ketosis may be effective against absence epileptic activity (Ross et al., 1985; Groomes et al., 2011; Thammongkol et al., 2012; Clemens et al., 2013; Kim et al., 2016; Lee et al., 2016). Our results suggest that not only KD, but also sub-chronically applied ketone supplements KE and KSMCT, administered by gavage, can increase βHB levels and decrease SWD number in freely moving WAG/Rij rats (Figures 3A–D). Moreover, SWD number and βHB level returned to the control level after both KE and KSMCT treatments (on the PT days). Thus, our results suggest that after ketone supplementation the absence epileptic activity can decrease in correlation with the increase in βHB level, which strengthens the support for nutritional ketosis as a means to suppress absence epileptic seizures (Ross et al., 1985; Groomes et al., 2011; Thammongkol et al., 2012; Clemens et al., 2013; Kim et al., 2016; Lee et al., 2016).

Moreover, it has been demonstrated that KD and ketone bodies (direct and/or indirect manner) among others may (i) increase adenosine signaling by both decreased expression/activity of adenosine kinase (which enzyme may metabolize adenosine) and enhanced βHB metabolism and, as a consequence, by A1Rs and (ii) enhance the inhibitory GABAergic effects in the brain by GABA_A receptors (Yudkoff et al., 2007; Masino et al., 2011, 2012; Sharma et al., 2015; Rho, 2017), which systems (GABAergic and adenosinergic) may have a role in the regulation of absence epileptic activity in WAG/Rij rats (Peeters et al., 1989; D’Alimonte et al., 2009; Kovács et al., 2015). It was demonstrated previously that activation of A2ARs and GABA_A receptors may evoke increases in SWD number in WAG/Rij rats.
### TABLE 3 | Changes in SWD number after i.p. injection of two doses of DPCPX (i.p. 0.2 mg/kg DPCPX: group 3; i.p. 0.5 mg/kg DPCPX: group 4).

| Treatments | The effect of treatment (two-way RM ANOVA; and Bonferroni’s post hoc test) | SWD number (mean ± SEM) |
|------------|--------------------------------------------------------------------------------|-------------------------|
| i.p. 0.2 mg/kg DPCPX (Figure 4A, group 3) | | |
| Control | −/1.979 | 15.9 ± 0.6 | 17.4 ± 0.4 |
| DPCPX | 15.7 ± 1.6 | −/1.271 | −/0.719 |
| i.p. 0.5 mg/kg DPCPX (Figure 4B, group 4) | | |
| Control | ***/102.700 | 15.4 ± 1.7 | 13.5 ± 1.3 |
| DPCPX | 28.7 ± 2.3 | ***/11.930 | −/2.406 |

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; SWD, spike-wave discharge. ***p < 0.001 level of significance.

### TABLE 4 | Effect of KSMCT gavage (2.5 g/kg/day; between 1st and 5th KSMCT treatment/1KS – 5KS and on the 7th day of KSMCT application/7KS) and combined application of DPCPX (i.p. 0.2 mg/kg) with KSMCT gavage (DPCPX + 6th KSMCT treatment/6KS + D, group 5) on SWD number.

| Treatments | The effect of treatment (one-way RM ANOVA; and Dunnett’s Multiple Comparison Test) | SWD number (mean ± SEM) |
|------------|--------------------------------------------------------------------------------|-------------------------|
| i.p. 0.2 mg/kg DPCPX + 2.5 g/kg/day KSMCT (Figure 4C, group 5) | | |
| Control (CON) | 30–90 min: ***/ | 17.9 ± 0.9 | 16.9 ± 0.8 |
| 1st KSMCT treatment (1KS) | 20.470 | 15.6 ± 1.7 | 15.7 ± 1.6 |
| 2nd KSMCT treatment (2KS) | **/4.829 | 13.1 ± 1.4 | 12.9 ± 0.7 |
| 3rd KSMCT treatment (3KS) | ***/7.257 | 10.7 ± 0.8 | 9.1 ± 0.7 |
| 4th KSMCT treatment (4KS) | ***/8.686 | 9.3 ± 1.1 | 9.4 ± 0.7 |
| 5th KSMCT treatment (5KS) | ***/9.543 | 8.4 ± 1.0 | 7.7 ± 0.5 |
| DPCPX + 6th KSMCT treatment (6KS+D) | ***/9.557 | 18.3 ± 0.9 | 16.4 ± 0.8 |
| 7th KSMCT treatment (7KS) | ***/8.829 | 9.1 ± 0.4 | 8.4 ± 0.7 |

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KSMCT, ketone salt/KS + medium chain triglyceride/MCT; SWD, spike-wave discharge. **p < 0.01 and ***p < 0.001 level of significance.

(D’Alimonte et al., 2009; Kovács et al., 2015; Lakatos et al., 2016), which results suggest that the modificatory effects of GABA<sub>A</sub> receptors and A<sub>2A</sub>Rs in ketone supplementation-evoked decrease in absence epileptic activity can be excluded. Density of A<sub>1</sub>Rs is uneven in the central nervous system, expression/activity of A<sub>1</sub>Rs is decreased in the somatosensory cortex (focus) and thalamus in presymptomatic WAG/Rij rats, A<sub>1</sub>Rs has a role in the modulation of different types of epilepsies, and KDs may exert their effect on epileptic activity by means of A<sub>1</sub>Rs (D’Alimonte et al., 2009; Kovács et al., 2011b, 2014; Masino et al., 2011). Furthermore, (i) SWDs triggered by excessive hyperexcitability in the cortical focus of absence epilepsy genesis (Meeren et al., 2002; Coenen and Van Luijtenbelaar, 2003), (ii) brain areas, implicated in absence epilepsy genesis, such as somatosensory cortex, contain A<sub>1</sub>Rs (Cremer et al., 2009; Kovács et al., 2011b) and (iii) not only KD, but also ketone supplementation may modulate adenosinergic system by increased adenosine levels (Masino et al., 2011; Sharma et al., 2015; Rho, 2017). It has been demonstrated previously that inhibition of A<sub>1</sub>Rs by DPCX induces seizure-like bursting activity in vitro (Thümmler and Dunwiddie, 2000) and A<sub>1</sub>R knockout mouse exhibits electrographic seizures in vivo (Masino et al., 2011). Moreover, in accordance with cortical focus theory of absence epilepsy (Meeren et al., 2002; Coenen and Van Luijtenbelaar, 2003), activation of inhibitory A<sub>1</sub>Rs, which may decrease
TABLE 5 | Influence of KE gavage (2.5 g/kg/day, 6th treatment, group 1), KSMCT gavage (2.5 g/kg/day, 6th treatment, group 2) and i.p. DPCPX (0.2 mg/kg, group 3) alone and combined application of i.p. DPCPX with KSMCT gavage (i.p. 0.2 mg/kg DPCPX + 6th KSMCT treatment, group 5) on average SWD duration and discharge frequency within SWDs between 30 and 90 min.

| Treatments                  | Average SWD duration (sec; (mean ± SEM) and Bonferroni's post hoc test (significance/t-value)) | Discharge frequency within SWDs (Hz; mean ± SEM) and Bonferroni's post hoc test (significance/t-value) |
|-----------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| 2.5 g/kg/day KE (group 1)   |                                                                                                 |                                                                                                |
| Control                     | 6.5 ± 0.6                                                                                        | 7.9 ± 0.1                                                                                        |
| 6th KE treatment            | 6.3 ± 0.7                                                                                        | 7.8 ± 0.1                                                                                        |
|                             | −/0.913                                                                                          | −/0.197                                                                                          |
| 2.5 g/kg/day KSMCT (group 2)|                                                                                                 |                                                                                                |
| Control                     | 6.6 ± 0.5                                                                                        | 7.8 ± 0.1                                                                                        |
| 6th KSMCT treatment         | 6.8 ± 0.7                                                                                        | 7.9 ± 0.1                                                                                        |
|                             | −/0.652                                                                                          | −/0.192                                                                                          |
| 0.2 mg/kg DPCPX (group 3)   |                                                                                                 |                                                                                                |
| Control                     | 6.5 ± 0.8                                                                                        | 7.8 ± 0.1                                                                                        |
| DPCPX                       | 6.3 ± 0.8                                                                                        | 7.8 ± 0.1                                                                                        |
|                             | −/0.044                                                                                          | −/0.199                                                                                          |
| i.p. 0.2 mg/kg DPCPX + 2.5 g/kg/day KSMCT (group 5) |                                                                                                 |                                                                                                |
| Control                     | 6.7 ± 0.7                                                                                        | 7.8 ± 0.1                                                                                        |
| DPCPX + 6th KSMCT treatment | 6.6 ± 0.7                                                                                        | 7.8 ± 0.1                                                                                        |
|                             | −/0.522                                                                                          | −/0.118                                                                                          |

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KE, ketone ester (1,3-butanediol - acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT; SWD, spike-wave discharge.

TABLE 6 | Changes in total time of sleep-waking stages and SWDs after KSMCT gavage (2.5 g/kg/day, 6th treatment, group 2) and DPCPX injection (i.p. 0.2 mg/kg, group 3) alone and combined application of i.p. DPCPX with KSMCT gavage (i.p. 0.2 mg/kg DPCPX + 6th KSMCT treatment, group 5) between 30 and 90 min.

| Treatments                  | Total duration of sleep-waking stages and SWDs (sec; mean ± SEM) and Bonferroni's post hoc test (significance/t-value) |
|-----------------------------|-------------------------------------------------------------------------------------------------|
| 2.5 g/kg/day KSMCT (6th KSMCT |                                                                                                 |
| treatment, group 2)         |                                                                                                 |
| Control                     | 702.7 ± 16.1                                                                                   |
| KSMCT                       | 720.8 ± 15.4                                                                                   |
| 6th Gavage                  | 675.8 ± 22.0                                                                                   |
| Control                     | 671.9 ± 19.3                                                                                   |
| i.p. 0.2 mg/kg DPCPX (group 3)|                                                                                                 |
| Control                     | 671.9 ± 19.3                                                                                   |
| DPCPX                       | 671.9 ± 19.3                                                                                   |
|                             | −/0.141                                                                                       |
| i.p. 0.2 mg/kg DPCPX + 2.5 g/kg/day KSMCT (6th KSMCT treatment, group 5) |                                                                                                 |
| Control                     | 688.2 ± 15.4                                                                                   |
| KSMCT                       | 697.5 ± 16.9                                                                                   |
| 6th KSMCT treatment         | 695.2 ± 16.8                                                                                   |
| Control                     | 704.7 ± 9.1                                                                                    |
| DPCPX                       | 696.5 ± 16.8                                                                                   |
|                             | −/0.440                                                                                       |

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KSMCT, ketone salt/KS + medium chain triglyceride/MCT; REM, rapid eye movement; SWD, spike-wave discharge; SWS, slow wave sleep; **p < 0.01 level of significance.

the excessive hyperexcitability in the somatosensory cortex (cortical focus) directly and indirectly by synaptic inhibition with reducing Ca$^{2+}$ influx through voltage-dependent Ca$^{2+}$ channels, and activation of both ATP-sensitive potassium (K$_{ATP}$) channels and G protein-gated inwardly rectifying potassium channels hyperpolarizing neuronal membranes (Kovács et al., 2014; Lusardi et al., 2015; Rho, 2017), may decrease absence epileptic activity. In addition, ketosis/ketone bodies may indirectly
activate $K_{ATP}$ channels (Ma et al., 2007). All of these inhibitory effects may be implicated in the modulatory effect of $A_1$Rs on KE and KSMCT treatment-evoked changes in epileptic seizures (Figure 4C), and/or strengthened the aggravating effect of higher dose of DPCPX on SWD number (Figure 4B) in WAG/Rij rats.

As to the antiepileptic effect of ketone supplementation, additional mechanisms of action similar to KD cannot be excluded (Rho, 2017). For example, depending on the diet formulation, KD/ketosis may result in (i) increased level of two potentially anti-convulsant fatty acids decanoic acid and octanoic acid, (ii) modified synaptic vesicle recycling by means of $\beta$HB (Chang et al., 2013; Hrynevich et al., 2016), (iii) appearance of adenosine-associated epigenetic mechanism(s) (Lusardi et al., 2015), (iv) increased threshold for calcium-induced mitochondrial permeability transition (Kim et al., 2015), and (v) decrease in extracellular glutamate release (Juge et al., 2010), which effects may also alleviate epileptic seizures. For example, it has been demonstrated that MCT may evoke anti-seizure effect by decanoic acid through AMPA receptor inhibition in vitro (Chang et al., 2016). Consequently, several mechanisms of action might be involved in KD- and ketone supplementation-evoked antiepileptic/antiseizure effects. However, our data are not sufficient to interpret all of the putative mechanisms, by which (i) exogenous ketone supplementation exerts its antiepileptic effects and (ii) $A_1$Rs modulate effects of ketone supplements on seizure activity.

CONCLUSION

The administration of exogenous ketone supplements without dietary restrictions (standard rodent diet) may be an effective alternative way to KD not only to reach and maintain nutritional ketosis, but also to reduce epileptic activity, and which can be reversed by inhibition of $A_1$Rs. Our results on WAG/Rij rats and modulation of ketone supplementation-evoked effects on absence epileptic activity provided an opportunity to investigate some new aspects of the pathophysiology of absence epilepsy, several signaling pathways, which are still poorly understood, influence of ketone supplementation on epileptic activity and the correlation between antiepileptic activity of ketone supplementation and their potential to induce ketosis. Our results may contribute to the development of effective antiepileptic strategies such as ketone supplementation not only against absence epilepsy (e.g., childhood absence epilepsy), but also for other therapy-resistant types of epilepsies, which may afford long-lasting seizure protection. Therefore, further studies are needed to reveal the exact molecular and neuropharmacological effects of exogenous ketone supplementation-induced decrease in absence epileptic activity and to disclose the putative link(s) between exogenous ketone supplements-evoked and adenosine-generated effects on seizure activity.

AUTHOR CONTRIBUTIONS

ZK: conception and design of experiments, data collection, interpretation of data, and writing manuscript, DD: interpretation of data, writing manuscript, AD: data analysis, writing manuscript, CA: conception and design of experiments, writing manuscript.

ACKNOWLEDGMENTS

This work was supported by ONR Grant N000141310062 (to DD), the National Development Agency of Hungary (under Grant No. TIOIP-1.3.1.-07/2-2F-2009-2008; ZK), and the National Development Agency of Hungary TÁMOP 4.2.1.-B-09/1/KMR-2010-0003, the KTIA_NAP_B_13-2-2014-0004 program (to AD).

We wish to thank Tamás Török (NYME SEK) for the technical assistance and the reviewers for providing helpful comments.

REFERENCES

Ari, C., Kovács, Z., Juhasz, G., Murdun, C., Goldhagen, C. R., Koutnik, A. M., et al. (2016). Exogenous ketone supplements reduce anxiety-related behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk rats. Front. Mol. Neurosci. 9:137. doi: 10.3389/fnmol.2017.00036

Bough, K. J., Gudi, K., Han, F. T., Rathod, A. H., and Eagles, D. A. (2002). An anticonvulsant profile of the ketogenic diet in the rat. Epilepsia Res. 50, 313–325. doi: 10.1016/S0920-1211(02)00086-4

Chang, P., Augustin, K., Boddum, K., Williams, S., Sun, M., Terschak, J. A., et al. (2016). Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain 139, 431–443. doi: 10.1093/brain/awv325

Chang, P., Terbach, N., Plant, N., Chen, P. E., Walker, M. C., and Williams, R. S. (2013). Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropeharmacology 69, 105–114. doi: 10.1016/j.neuropharm.2012.11.004

Clemens, Z., Kelemen, A., Fogaras, A., and Tóth, C. (2013). Childhood absence epilepsy successfully treated with the paleolithic ketogenic diet. Neurol. Ther. 2, 71–76. doi: 10.1007/s40412-013-0013-2

Coenen, A. M., Drinkenburg, W. H., Peeters, B. W., Vossen, J. M., and Van Luijtelaar, E. L. (1991). Absence epilepsy and the level of vigilance in rats of the WAG/Rij strain. Neurosci. Biobehav. Rev. 15, 259–263. doi: 10.1016/S0149-7634(05)80005-3

Coenen, A. M., and Van Luijtelaar, E. L. (2003). Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats. Behav. Genet. 33, 635–655. doi: 10.1023/A:1026179013847

Cremer, C. M., Palomo-Gallagher, N., Bidmon, H. J., Schleicher, A., Speckmann, E. J., and Zilles, K. (2009). Pentylenetetrazol-induced seizures affect binding site densities for GABA, glutamate and adenosine receptors in the rat brain. Neuroscience 163, 490–499. doi: 10.1016/j.neuroscience.2009.03.068

D’Agostino, D., Pilla, R., Held, H., Landon, C., Puchowicz, M., Brunengraber, H., et al. (2013). Therapeutic ketosis with ketogenic ester delays central nervous system oxygen toxicity seizures in rats. Am. J. Phys. Reg. Integr. Comp. Phys. 304, 829–836. doi: 10.1152/ajpregu.00506.2012

D’Alimonte, I., D’Auro, M., Citraro, R., Biagioni, F., Jiang, S., Nargi, E., et al. (2009). Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. Eur. J. Neurosci. 30, 1023–1035. doi: 10.1111/j.1460-9586.2009.06897.x

Freeman, J. M., Kelly, M. T., and Freeman, J. B. (1994). The Epilepsy Diet Treatment: An Introduction to the Ketogenic Diet. New York, NY: Demos.
Lusardi, T. A., Akula, K. K., Coffman, S. Q., Ruskin, D. N., Masino, S. A., Kovács, Z., Kékesi, K. A., Szilágyi, N., Ábrahám, I., Székács, D., Király, N., et al. (2014). The antiepileptic
effect of intraperitoneally administered dimethyl sulfoxide on absence-like epileptic activity of freely moving WAG/Rij rats. *J. Neurosci. Methods* 197, 133–136.
doi: 10.1016/j.jneumeth.2011.02.005

Kovács, Z., Czurkó, Á., Kékesi, K. A., and Juhász, G. (2011a). The effect of high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children.
*Pediatr. Neurol.* 45, 1171–1176. doi: 10.1016/j.pediatrneurol.2011.07.014

Ross, D. L., Swaiman, K. F., Torres, F., and Hansen, J. (1985). Early biochemical and EEG correlates of the ketogenic diet in children with atypical absence epilepsy.
*Pediatr. Neurol.* 5, 60–63.

Kim, D. Y., Simeone, J. D., Wilke, J. C., Ahn, Y., Juge, N., Gray, J. A., Omote, H., Miyaji, T., Inoue, T., Hara, C., et al. (2010). Guanosine may increase absence epileptic activity by means of A2A adenosine receptors in Wistar Albino Glaxo Rijswijk rats.
*Epilepsia* 51, 1109–1117. doi: 10.1111/j.1528-1167.2008.01394.x

Hrynevich, S. V., Waseem, T. V., Hébert, A., Pellerin, L., and Fedorovich, S. V. (2016). β-Hydroxybutyrate supports synaptic vesicle cycling but reduces endocytosis and exocytosis in rat brain synaptosomes.
*Neurochem. Int.* 93, 73–81. doi: 10.1016/j.neuint.2015.12.014

Kim, J. A., Yoon, J. R., Lee, E. J., Lee, J. S., Kim, J. T., Kim, H. D., et al. (2016). Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. *Epilepsia* 57, 51–58. doi: 10.1111/epi.13256

Kossoff, E. H. (2002). Cortical focus drives widespread corticothalamic networks during the anticonvulsant effect.
*Annu. Rev. Nutr.* 22, 500–509. doi: 10.1146/annurev.nutr.22.051701.10376443

Gromoes, L. B., Pfyzer, P. L., Turner, Z., Dorward, J. L., Goode, V. H., and Kossoff, E. H. (2011). Do patients with absence epilepsy respond to ketogenic diets?
*J. Child Neurol.* 26, 160–165. doi: 10.1177/0883073810376443

Gilbert, D. L., Pysz, P. L., and Freeman, J. M. (2000). The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.
*J. Child Neurol.* 15, 787–790. doi: 10.1077/08830738001501203

Hrynevich, S. V., Waseem, T. V., Hébert, A., Pellerin, L., and Fedorovich, S. V. (2016). β-Hydroxybutyrate supports synaptic vesicle cycling but reduces endocytosis and exocytosis in rat brain synaptosomes.
*Neurochem. Int.* 93, 73–81. doi: 10.1016/j.neuint.2015.12.014

Juge, N., Gray, I. A., Omote, H., Miyaji, T., Inoue, T., Hara, C., et al. (2010). Guanosine may increase absence epileptic activity by means of A2A adenosine receptors in Wistar Albino Glaxo Rijswijk rats.
*Epilepsia* 51, 1109–1117. doi: 10.1111/j.1528-1167.2008.01394.x

Lee, E., Kang, H. C., and Kim, H. D. (2016). Ketogenic diet for children with epilepsy: a practical meal plan in a hospital.
*Pediatr. Neurol.* 57, 51–58. doi: 10.1111/epi.13256

Lee, E., Kang, H. C., and Kim, H. D. (2016). Ketogenic diet for children with epilepsy: a practical meal plan in a hospital.
*Pediatr. Neurol.* 57, 51–58. doi: 10.1111/epi.13256

Kovács, Z., Juhász, G., Palkovits, M., Dobolyi, A., and Kékesi, K. A. (2011b). The effect of intraperitoneally administered dimethyl sulfoxide on absence-like epileptic activity of freely moving WAG/Rij rats. *J. Neurosci. Methods* 197, 133–136.
doi: 10.1016/j.jneumeth.2011.02.005

Kovács, Z., Czurkó, Á., Kékesi, K. A., and Juhász, G. (2011a). The effect of high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children.
*Pediatr. Neurol.* 45, 1171–1176. doi: 10.1016/j.pediatrneurol.2011.07.014

Kim, D. Y., Simeone, K. A., Simeone, T. A., Pandya, J. D., Wilke, J. C., Ahn, Y., et al. (2015). Ketone bodies mediate antiseizure effects through mitochondrial permeability transition.
*Ann. Neurol.* 78, 77–87. doi: 10.1002/ana.24424

Kovács, Z., Juhász, G., Palkovits, M., Dobolyi, A., and Kékesi, K. A. (2011b). The effect of intraperitoneally administered dimethyl sulfoxide on absence-like epileptic activity of freely moving WAG/Rij rats. *J. Neurosci. Methods* 197, 133–136.
doi: 10.1016/j.jneumeth.2011.02.005

Kovács, Z., Juhász, G., Palkovits, M., Dobolyi, A., and Kékesi, K. A. (2011b). The effect of intraperitoneally administered dimethyl sulfoxide on absence-like epileptic activity of freely moving WAG/Rij rats. *J. Neurosci. Methods* 197, 133–136.
doi: 10.1016/j.jneumeth.2011.02.005

Kossoff, E. H., Freeman, J. M., Turner, Z., and Rubenstein, J. E. (2011). Ketogenic Diets: Treatments for Epilepsy and other Disorders, 5th Edn. New York, NY: Demos Medical.

Kovács, Z., Czurkó, Á., Kékesi, K. A., and Juhász, G. (2011a). The effect of high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children.
*Pediatr. Neurol.* 45, 1171–1176. doi: 10.1016/j.pediatrneurol.2011.07.014

Kossoff, E. H., Freeman, J. M., Turner, Z., and Rubenstein, J. E. (2011). Ketogenic Diets: Treatments for Epilepsy and other Disorders, 5th Edn. New York, NY: Demos Medical.

Kossoff, E. H., Freeman, J. M., Turner, Z., and Rubenstein, J. E. (2011). Ketogenic Diets: Treatments for Epilepsy and other Disorders, 5th Edn. New York, NY: Demos Medical.

Kossoff, E. H. (2002). Cortical focus drives widespread corticothalamic networks during the anticonvulsant effect.
*Annu. Rev. Nutr.* 22, 500–509. doi: 10.1146/annurev.nutr.22.051701.10376443

Kossoff, E. H., Freeman, J. M., Turner, Z., and Rubenstein, J. E. (2011). Ketogenic Diets: Treatments for Epilepsy and other Disorders, 5th Edn. New York, NY: Demos Medical.

Kossoff, E. H. (2002). Cortical focus drives widespread corticothalamic networks during the anticonvulsant effect.
*Annu. Rev. Nutr.* 22, 500–509. doi: 10.1146/annurev.nutr.22.051701.10376443

Kossoff, E. H. (2002). Cortical focus drives widespread corticothalamic networks during the anticonvulsant effect.
*Annu. Rev. Nutr.* 22, 500–509. doi: 10.1146/annurev.nutr.22.051701.10376443